Still on Wegovy but not losing weight — what's actually going on

You're at an early dose and semaglutide hasn't reached full strength yet

Picture this: it's week six, you're on 0.5mg, you feel vaguely less hungry than before, but the weight loss is modest at best. This is one of the most common situations our prescribers field, people who assumed the medicine would work in a straight line from day one.

It doesn't, and that's by design. Wegovy starts at 0.25mg for at least four weeks, then steps up through 0.5mg, 1mg, 1.7mg, and finally to 2.4mg, with roughly a month at each level. The purpose of the earlier doses is to let your body adjust and reduce the likelihood of severe nausea, they are not expected to produce the same appetite suppression as the maintenance dose. How long Wegovy takes to work depends heavily on where you are in that ladder, and the clinical trial evidence underpinning NICE's recommendation for semaglutide was based on the 2.4mg maintenance dose. If you're not there yet, measured patience is medically appropriate.

The STEP 1 trial, published in the New England Journal of Medicine, reported an average weight reduction of around 15% at 2.4mg over 68 weeks. That figure comes from people who completed the full titration. Progress before then is typically slower and less linear than most people expect going in.

The 'eating less but eating differently' trap

Once the worst of the early nausea fades (usually after a dose increase settles) appetite-suppression can feel less dramatic. People eat smaller portions at mealtimes, which is working as intended, but then find themselves snacking more between meals without registering it as eating. The medicine blunts hunger signals tied to stomach fullness; it has less influence over the habitual, reward-driven eating that happens in front of a screen or when you're bored.

Protein intake is worth paying attention to here. When overall food intake falls, people who don't prioritise protein tend to lose muscle alongside fat, which reduces how many calories the body burns at rest, making further loss harder over time. NHS guidance on semaglutide and the wider obesity-medicine wraparound advice both emphasise diet quality alongside the medicine, not simply eating less of everything.

A food diary (even for a week) often reveals the gap between estimated and actual intake. It's not about judgment; it's about data. A brief conversation with a dietitian can do more at this stage than any dose tweak.

Your other medicines may be working against you

This is something that doesn't get mentioned enough outside a consultation room. Several widely prescribed medicines are associated with clinically meaningful weight gain or resistance to loss: certain antidepressants (particularly mirtazapine and some SSRIs at higher doses), antipsychotics, corticosteroids taken long-term, some insulin regimens, and certain beta-blockers and anticonvulsants.

If you started one of these medicines around the same time as Wegovy, or have been on them for a while, they may be offsetting some of what semaglutide is doing. This isn't a reason to stop your other medicines, it's a reason to raise it with your prescriber. There are sometimes alternatives, and knowing the interaction helps set realistic expectations. A good place to start is understanding all the reasons weight loss can stall on semaglutide before drawing conclusions about the medicine itself.

The same review applies to thyroid function, unmanaged or undertreated hypothyroidism makes weight loss difficult regardless of what else you're taking, and a simple blood test rules it out.

When to raise it with a prescriber, and what they'll look at

A plateau of two to four weeks is normal at any stage. A plateau of eight or more weeks, with no change in either direction and no obvious explanation, is worth discussing formally. So is any plateau accompanied by side effects that have been difficult to manage, because persistent nausea sometimes causes people to eat patterns that don't serve weight loss even while it feels restrictive.

The NHS notes that stopping treatment should be considered if less than 5% weight loss is achieved after six months at the maintenance dose. That's a clinical threshold for prescribers, not a reason to self-stop early, but it does mean there's a formal review point built into this medicine's use. If you're approaching or past that point, a structured conversation about your next step is the right move, not simply waiting it out.

nume's prescribers review every patient before each repeat is issued. If something in your progress pattern warrants a closer look (whether that's the dose, the timing, or a parallel medicine review) that's exactly what the clinical re-review is for. If you're specifically not seeing any movement at all on Wegovy, there are dedicated clinical considerations that go beyond a standard plateau review. Similarly, if you've been wondering whether not losing weight on semaglutide points to something specific about how the drug is working for you, that page covers the evidence in more detail. For pricing context on continued treatment, the Wegovy pricing page lays out what's included in each order. When you're ready to speak with a clinician directly, starting a free consultation puts your case in front of a GPhC-registered prescriber, not a chatbot, the same day.